CEACAM5 and colorectal carcinoma: Specifically, the mSEPT9 DNA marker, with a sensitivity of 72.94% and specificity of 81.97%, outperforms traditional markers like CEA and CA19‐9 in differentiating CRC patients from healthy controls.247